Triptan and ergotamine overdoses in the United States
- 7 April 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 94 (14) , e1460-e1469
Abstract
Objective To examine the clinical outcomes of intentional overdoses involving triptans and ergotamines with a retrospective review of the National Poison Data System (NPDS). Methods This was a 5-year retrospective cross-sectional study (2014–2018) using the NPDS. Demographics, exposure characteristics, and outcomes were described. Univariate logistic regression was used to estimate the odds ratio (OR) for major effect or death. A multivariable logistic regression model with inclusion criteria of p < 0.1 in univariate analysis was implemented with backwards selection. Results In this population (n = 1,489), multiple exposure was most common (n = 1,145). The mean age was 31.2 years and 1,197 (80.4%) participants were female. Major effects from a single exposure were seen in p = 0.004), multiple product exposure (OR 9.50; 95% CI 2.29–39.48; p = 0.002), and concomitant overdose with benzodiazepines (OR 1.71; 95% CI 1.05–2.78; p = 0.032) or tricyclic antidepressants (OR 3.16; 95% CI 1.88–5.31; p < 0.001). Conclusion The risk of major effect or death was low and predicted by age, multiple product exposure, and concomitant benzodiazepine or tricyclic antidepressant. The triptan toxidrome consists of hypertension, tachycardia, and drowsiness. The toxic effects of ergotamine are acute gastrointestinal syndrome with vertigo and numbness. No cases of serotonin syndrome were seen.Keywords
This publication has 30 references indexed in Scilit:
- Dihydroergotamine, Ergotamine, Methysergide and Sumatriptan – Basic Science in Relation to Migraine TreatmentHeadache: The Journal of Head and Face Pain, 2012
- Serotonin Syndrome: SSRIs, SNRIs, Triptans, and Current Clinical PracticeHeadache: The Journal of Head and Face Pain, 2012
- Evaluation of the Migraine Treatment Sumatriptan/Naproxen Sodium on Blood Pressure Following Long-Term AdministrationThe Journal of Clinical Hypertension, 2011
- The FDA Alert on Serotonin Syndrome With Use of Triptans Combined With Selective Serotonin Reuptake Inhibitors or Selective Serotonin‐Norepinephrine Reuptake Inhibitors: American Headache Society Position PaperHeadache: The Journal of Head and Face Pain, 2010
- The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicityQJM: An International Journal of Medicine, 2003
- The comparison of the responsiveness of human isolated internal mammary and gastroepiploic arteries to levcromakalim: an alternative approachto the management of graft spasmBritish Journal of Clinical Pharmacology, 1997
- 311C90, A new central and peripherally acting 5-HT 1D receptor agonist in the acute oral treatment of migraineNeurology, 1996
- Effect of subcutaneous sumatriptan, a selective 5HT1 agonist, on the systemic, pulmonary, and coronary circulation.Circulation, 1993
- Treatment of Acute Cluster Headache with SumatriptanNew England Journal of Medicine, 1991
- Treatment of Migraine Attacks with SumatriptanNew England Journal of Medicine, 1991